Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Acq. announced
Quarterly results
Director departure
Appointed director
WaferGen Bio-systems, Inc. (WGBS) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/08/2016 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Results for Third Quarter 2016 Year-to-Date Revenues Represent 44% Growth over First Nine Months of 2015 FREMONT, California – November 8, 2016 – WaferGen Bio-systems, Inc. , a life sciences company focused on developing and commercializing technology platforms for genomic solutions, announced today its financial results for the third quarter ended September 30, 2016. Key Recent Highlights"
08/09/2016 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Results for Second Quarter 2016 Second Quarter Revenues Represent 56% Growth over Second Quarter of 2015 and 30% Growth over First Quarter of 2016 FREMONT, California – August 9, 2016 – WaferGen Bio-systems, Inc. , a life sciences company focused on developing and commercializing technology platforms for genomic solutions, announced today its financial results for the second quarter ended June 30, 2016. Key Recent Highlights"
05/10/2016 8-K Form 8-K - Current report
03/08/2016 8-K Form 8-K - Current report
11/10/2015 8-K Quarterly results
Docs: "15Q3ER"
08/05/2015 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Results for Second Quarter 2015 Company Continues to Advance Single Cell Analysis Technology According to Plan; Full Commercial Launch on Track for Fourth Quarter of 2015 Early Access Program for WaferGen’s Single Cell Analysis Technology Fully Enrolled; Initial Data Anticipated in Third Quarter FREMONT, California -- August 5, 2015 – WaferGen Bio-systems, Inc. announced today its financial results for the second quarter and six months ended June 30, 2015. Key Recent Highlights"
05/11/2015 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Results for First Quarter 2015 Company Continues to Advance Single Cell Analysis Technology, Full Commercial Launch Expected by End of 2015 Early Access Program for WaferGen’s Single Cell Analysis Technology Initiated; Company Collaborating with Genentech, National Jewish Hospital and Karolinska Institutet Company Reiterates 2015 Revenue Guidance"
03/16/2015 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Results for Fourth Quarter and Fiscal Year 2014 Record Growth in 2014 Revenues, up 360 Percent over 2013 Significant Progress Achieved with Single Cell Analysis Technology, Full Commercial Launch Expected by End of 2015 Company Provides 2015 Revenue Guidance of $8.0 - $8.5 Million, Which Would Represent an Increase of 33% - 42% FREMONT, California -- March 16, 2015 /PRNewswire/ – WaferGen Bio-systems, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2014. Key 2014 and Recent Highlights"
11/07/2014 8-K Quarterly results
Docs: "WaferGen Bio-systems Announces Third Quarter 2014 Results Solid Execution Across SmartChip and Apollo Product Lines Appointment of Chief Operating Officer and Chief Financial Officer Completion of $20 million offering of Common Stock and Warrants"
08/07/2014 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Strong Revenue Growth for Q2 2014 Solid Execution Across SmartChip and Apollo Product Lines FREMONT, Calif., August 7, 2014 /PRNewswire/ -- WaferGen Bio-systems, Inc. announced today its financial results for the second quarter ended June 30, 2014. Key Highlights"
05/08/2014 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Strong Revenue Growth for Q1 2014 Solid Execution Across SmartChip and Apollo Product Lines Company Increases Full Year 2014 Revenue Guidance from over $5 million to over $6 million FREMONT, Calif., May 8, 2014 /PRNewswire/ -- WaferGen Bio-systems, Inc. announced today its financial results for the first quarter ended March 31, 2014. Key Highlights"
03/13/2014 8-K Quarterly results
Docs: "WaferGen Bio-systems Reports Solid Revenue Growth for Q4 and the Year 2013 Enters 2014 with enhanced balance sheet and primed for further growth with acquisition of the Apollo 324TM product line FREMONT, Calif., March 13, 2014 /PRNewswire/ -- WaferGen Bio-systems, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Key Highlights"
11/21/2011 8-K Form 8-K - Current report
09/12/2011 8-K Form 8-K - Current report
05/16/2011 8-K Form 8-K - Current report
08/16/2010 8-K Form 8-K - Current report
11/13/2008 8-K Quarterly results
Docs: "WaferGen Announces Third Quarter 2008 Financial Results Fremont, CA, November 10, 2008 – WaferGen Biosystems, Inc. , a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today highlighted the company’s recent developments and announced financial results for the quarter and nine months ended September 30, 2008. Recent Corporate Developments:"
08/14/2008 8-K Quarterly results
Docs: "WaferGen Announces Second Quarter 2008 Financial Results Fremont, CA, August 13, 2008 –WaferGen Biosystems, Inc. , a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today highlighted the company’s recent developments and milestones and announced financial results for the quarter and six months ended June 30, 2008. Recent Corporate Developments and Milestones:"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy